New approaches to transcutaneous immunotherapy: Targeting dendritic cells with novel allergen conjugates

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 6, 2013, Pages 669-676

  Weiss, Richard ^a   Scheiblhofer, Sandra ^a   Machado, Yoan ^a   Thalhamer, Josef ^a  

^a UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Allergen conjugates; C type lectin receptors; Carbohydrates; Dendritic cells; Transcutaneous immunotherapy

Indexed keywords

ALLERGEN; CHITOSAN; DECTIN 1; EPITOPE; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 12; LECTIN RECEPTOR; MANNAN; NANOPARTICLE; OVALBUMIN; PATTERN RECOGNITION RECEPTOR; POLLEN ANTIGEN; SEPHAROSE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 9; VACCINE;

ALLERGENICITY; ANTIBODY TITER; ANTIGEN PRESENTATION; B LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONJUGATE; CROSS LINKING; DENDRITIC CELL; ECZEMA; EOSINOPHILIA; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATION; KERATINOCYTE; LANGERHANS CELL; MACROPHAGE; MAST CELL; NONHUMAN; NOSE PROVOCATION TEST; PATHOGENESIS; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT ALLERGY; REVIEW; SAFETY; SENSITIZATION; SKIN PERMEABILITY; T LYMPHOCYTE ACTIVATION; TARGET ORGAN; TH2 CELL; TRANSCUTANEOUS IMMUNOTHERAPY; TREATMENT DURATION; URTICARIA; VIRUS LIKE AGENT;

ALLERGENS; DENDRITIC CELLS; DESENSITIZATION, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; EPITOPES, B-LYMPHOCYTE; HYPERSENSITIVITY; IMMUNIZATION;

EID: 84889825468     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328364f4df     Document Type: Review

References (60)

1. Kiel MA, Roder E, Gerth van Wijk R, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013; 132:353-360.e2.
2. Hylander T, Latif L, Petersson-Westin U, et al. Intralymphatic allergen-specific immunotherapy: An effective and safe alternative treatment route for polleninduced allergic rhinitis. J Allergy Clin Immunol 2013; 131:412-420.
3. Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012; 129:1290-1296.
4. Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009; 124:997-1002.
5. Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A doubleblind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012; 129:128-135. Follow-up study demonstrating efficacy of epicutaneous allergen-specific immunotherapy against grass pollen in a dose-dependent manner, showing symptom relief after only six applications.
6. Agostinis F, Forti S, Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinocon junctivitis. Allergy 2010; 65:404-411.
7. Dupont C, Kalach N, Soulaines P, et al. Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010; 125:1165-1167.
8. Bach D, Weiss R, Hessenberger M, et al. Transcutaneous immunotherapy via laser-generated micropores efficiently alleviates allergic asthma in Phl p 5-sensitized mice. Allergy 2012; 67:1365-1374. Transcutaneous immunization via laser-generated micropores shows similar efficiency as SCIT in a mouse model of allergic asthma, but induces fewer therapy induced side-effects.
9. Hessenberger M, Weiss R, Weinberger EE, et al. Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores. Vaccine 2013; 31:3427-3434.
10. Mondoulet L, Dioszeghy V, Ligouis M, et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010; 40:659-667.
11. Mondoulet L, Dioszeghy V, Vanoirbeek JA, et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 2011; 154:299-309.
12. Dioszeghy V, Mondoulet L, Dhelft V, et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 2011; 186:5629-5637.
13. Mondoulet L, Dioszeghy V, Larcher T, et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS ONE 2012; 7: e31967.
14. Mondoulet L, Dioszeghy V, Puteaux E, et al. Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice. Clin Transl Allergy 2012; 2:22. This study demonstrates that in mice epicutaneous immunotherapy with peanut allergen on intact skin induces FoxP3 ;T cells while application to tape-stripped skin reinforces TH2 immune responses.
15. Garaczi E, Szabo K, Francziszti L, et al. DermAll nanomedicine for allergenspecific immunotherapy. Nanomedicine 2013. [Epub ahead of print]
16. Combadiere B, Liard C. Transcutaneous intradermal vaccination. Hum Vaccin 2011; 7:811-827.
17. Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling. Presse Med 1959; 67:2299-2301.
18. De Benedetto A, Kubo A, Beck LA. Skin barrier disruption: A requirement for allergen sensitization? J Invest Dermatol 2012; 132:949-963.
19. Gutowska-Owsiak D, Ogg GS. The epidermis as an adjuvant. J Invest Dermatol 2012; 132:940-948.
20. Strid J, Sobolev O, Zafirova B, et al. The intraepithelial T cell response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science 2011; 334:1293-1297.
21. Nakajima S, Igyarto BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol 2012; 129:1048-1055. Epicutaneous sensitization is dependent on epidermal, but not dermal Langerin ; cells expressing the TSLP receptor.
22. Oyoshi MK, Larson RP, Ziegler SF, et al. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression. J Allergy Clin Immunol 2010; 126:976-984.
23. Otsuka A, Kubo M, Honda T, et al. Requirement of interaction between mast cells and skin dendritic cells to establish contact hypersensitivity. PLoS ONE 2011; 6: e25538.
24. Scheiblhofer S, Thalhamer J, Weiss R. Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines. Expert Opin Drug Deliv 2013; 10:761-773.
25. Weldon WC, Zarnitsyn VG, Esser ES, et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS ONE 2012; 7: e41501.
26. Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38:1404-1413.
27. Ruff LE, Mahmoud EA, Sankaranarayanan J, et al. Antigen-loaded pH-sensitive hydrogel microparticles are taken up by dendritic cells with no requirement for targeting antibodies. Integr Biol (Camb) 2013; 5:195-203.
28. Baleeiro RB, Wiesmuller KH, Reiter Y, et al. Topical vaccination with functionalized particles targeting dendritic cells. J Invest Dermatol 2013; 133:1933-1941.
29. Ejaz A, Ammann CG, Werner R, et al. Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses. PLoS One 2012; 7: e45102.
30. Caminschi I, Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol 2012; 33:71-77.
31. Caminschi I, Maraskovsky E, Heath WR. Targeting dendritic cells in vivo for cancer therapy. Front Immunol 2012; 3:13.
32. Lepenies B, Lee J, Sonkaria S. Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Deliv Rev 2013. [Epub ahead of print]
33. Do Y, Didierlaurent AM, Ryu S, et al. Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor. Vaccine 2012; 30:6359-6367.
34. Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin DEC205, and Clec9A. Proc Natl Acad Sci U S A 2011; 108:2384-2389.
35. Hemmi H, Zaidi N, Wang B, et al. Treml4, an Ig superfamily member, mediates presentation of several antigens to T cells in vivo, including protective immunity to HER2 protein. J Immunol 2012; 188:1147-1155.
36. Leung CS, Maurer MA, Meixlsperger S, et al. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205. Blood 2013; 121:1584-1594. DEC205 is expressed not only on dendritic cells but also on activated B cells. The efficiency of DEC205 targeted vaccines is in part dependent on antigen presentation by B cells.
37. Idoyaga J, Fiorese C, Zbytnuik L, et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844-854. This study demonstrates that migratory dendritic cells have a superior ability to generate Treg in vivo, providing a rationale for the superiority of epicutaneous or transcutaneous immunotherapy compared with SCIT.
38. Gringhuis SI, den Dunnen J, Litjens M, et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nat Immunol 2009; 10:203-213.
39. Gringhuis SI, Kaptein TM, Wevers BA, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat Immunol 2012; 13:246-254.
40. Chen ST, Liu RS, Wu MF, et al. CLEC5A regulates Japanese encephalitis virus-induced neuroinflammation and lethality. PLoS Pathog 2012; 8: e1002655.
41. WuMF, Chen ST, Yang AH, et al. CLEC5A is critical for dengue virus-induced inflammasome activation in human macrophages. Blood 2013; 121:95-106.
42. Shenderov K, Barber DL, Mayer-Barber KD, et al. Cord factor and peptidoglycan recapitulate the Th17-promoting adjuvant activity of mycobacteria through mincle/CARD9 signaling and the inflammasome. J Immunol 2013; 190:5722-5730.
43. Miyake Y, Toyonaga K, Mori D, et al. C-type lectin MCL is an FcRgammacoupled receptor that mediates the adjuvanticity of mycobacterial cord factor. Immunity 2013; 38:1050-1062.
44. Gringhuis SI, den Dunnen J, Litjens M, et al. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis HIV-1 and Helicobacter pylori. Nat Immunol 2009; 10:1081-1088.
45. van Vliet SJ, Bay S, Vuist IM, et al. MGL signaling augments TLR2-mediated responses for enhanced IL-10 and TNF-alpha secretion. J Leukoc Biol 2013; 94:315-323.
46. Eberle ME, Dalpke AH. Dectin-1 stimulation induces suppressor of cytokine signaling 1, thereby modulating TLR signaling and T cell responses. J Immunol 2012; 188:5644-5654.
47. van den Berg LM, Gringhuis SI, Geijtenbeek TB. An evolutionary perspective on C-type lectins in infection and immunity. Ann N Y Acad Sci 2012; 1253:149-158.
48. Royer PJ, Emara M, Yang C, et al. The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. J Immunol 2010; 185:1522-1531.
49. Emara M, Royer PJ, Abbas Z, et al. Recognition of the major cat allergen Fel d 1 through the cysteine-rich domain of the mannose receptor determines its allergenicity. J Biol Chem 2011; 286:13033-13040.
50. Hsu SC, Chen CH, Tsai SH, et al. Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN), on human dendritic cells. J Biol Chem 2010; 285:7903-7910.
51. Emara M, Royer PJ, Mahdavi J, et al. Retagging identifies dendritic cellspecific intercellular adhesion molecule-3 (ICAM3)-grabbing nonintegrin (DC-SIGN) protein as a novel receptor for a major allergen from house dust mite. J Biol Chem 2012; 287:5756-5763.
52. ChieppaM, Bianchi G, Doni A, et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 2003; 171:4552-4560.
53. Nakaira-Takahagi E, Golim MA, Bannwart CF, et al. Interactions between TLR2, TLR4, and mannose receptors with gp43 from Paracoccidioides brasiliensis induce cytokine production by human monocytes. Med Mycol 2011; 49:694-703.
54. Feriotti C, Loures FV, Frank de Araujo E, et al. Mannosyl-recognizing receptors induce an M1-like phenotype in macrophages of susceptible mice but an M2-like phenotype in mice resistant to a fungal infection. PLoS ONE 2013; 8:e54845.
55. Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-547.
56. Weinberger EE, Himly M, Myschik J, et al. Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: A novel tool for specific immunotherapy. J Control Release 2013; 165:101-109. This study descibes the generation of nanoparticles by cross-linking allergens with carbohydrates. These particles demonstrated reduced allergenicity and enhanced dendritic cell targeting and immunogenicity making them promising candidates for transcutaneous immunotherapy.
57. Andersson TN, Ekman GJ, Gronlund H, et al. A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro. Immunology 2004; 113:253-259.
58. Thunberg S, Neimert-Andersson T, Cheng Q, et al. Prolonged antigenexposure with carbohydrate particle based vaccination prevents allergic immune responses in sensitized mice. Allergy 2009; 64:919-926.
59. Saint-Lu N, Tourdot S, Razafindratsita A, et al. Targeting the allergen to oral dendritic cells with mucoadhesive chitosan particles enhances tolerance induction. Allergy 2009; 64:1003-1013.
60. Mascarell L, Saint-Lu N, Moussu H, et al.Oral macrophage-like cells play a key role in tolerance induction following sublingual immunotherapy of asthmatic mice. Mucosal Immunol 2011; 4:638-647.